Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The global immune health supplements market is expected to grow from $54.95B in 2022 to $61.34B in 2023, at a CAGR of 11.6%, according to a report by Research & Markets. The immune health supplements market is expected to grow to $95.19B n in 2027 at a CAGR of 11.6%.
read more
The U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause.
read more
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer's disease. This is the first FDA-approved treatment option for this indication.
read more
The nutraceuticals market is projected to grow by $223.56B from 2022 to 2027, at a CAGR of 8.46%, according to a report by Tachnavio.
read more
The global empty capsules market was valued at $2.69B in 2022 and is expected to expand to USD 6B in 2030 at a CAGR of 10.57% from 2023 to2030, according to a report from Research & Markets.
read more
Servier, a global pharmaceutical group, announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a targeted therapy in two indications: in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are...
read more
The gummy supplements market is projected to reach $48.5B by 2028 from $24.6B by 2023, at a CAGR of 14.5% from 2023 to 2028, according to a new report by MarketsandMarkets™.
read more
The probiotic dietary supplements market reached a value of nearly $6.39B in 2022, having grown at a compound annual growth rate (CAGR) of 7.7% since 2017. The market is expected to grow to $9,4B in 2027 and hit $14.79B in 2032.
read more
The global weight loss supplement market is estimated to grow by $2B from 2022 to 2027, according to Technavio. Growth is projected at a CAGR of 6.75% during the forecast period. North America is estimated to account for 29% of the market growth during the forecast period.
read more
Gummy supplement manufacturer TopGum, Ltd. launches Gummiccino™, its new line of
high-dosage caffeine gummies. The product marks the first use of TopGum’s new proprietary microencapsulation technology designed to enhance flavor and boost absorption.
read more
Aurinia Pharmaceuticals announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS® (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V (including mixed classes III/V and IV/V) lupus nephritis (LN), a serious complication ...
read more
The global digestive remedies market in 2022 stood at $18.71B, and is likely to reach $23.53B by 2028, according to a report by Research & Markets.
read more
Teva Pharmaceuticals USA is recalling specific lots of various strengths of Fentanyl Buccal Tablets. Teva USA manufactured and labeled these product lots exclusively for Mayne Pharma Inc. under Mayne’s label. This recall has been initiated because safety updates were omitted in the Product Insert/Medication Guide that are provided with these ...
read more
U.S. marshals, at the FDA’s request, seized more than 250,000 units of dietary supplements and bulk dietary ingredients that are or contain kratom, including over 1000 kilograms of bulk kratom.
read more
The beta-glucan market is estimated at $501M in 2023 and is projected to reach $734M by 2028, at a CAGR of 7.9% from 2023 to 2028 according to a report by MarketsandMarkets™.
read more